3JAMES C,UGO V, LE COU E DIC JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemi a vera [J]. Nature,2005,434 : 1144-1148.
4BAXTER EJ,SCOTT LM,CAMPHELL PJ,et al. Acquire mutation of the tyrosine kinasc JAK2 in human myeloproliferative disorders [ J ]. Lancet, 2005,365 : 1054 - 1061.
5LEVINE RL, WADLEIGH M, COOLS J, et al. Activiting mutation in the turosine kinase JAK2 polycuthaemia vera, essential thromboeythe- mia, and myeloid metaplasia with myelofibrosis [ J]. Cancer Cell, 2005,7:387-397.
6KRALOVICS R,PASSAMONTI F,BUSER AS,et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders[J]. N Engl J Med ,2005,352 : 1779-1790.
7TEFFERI, VARDIMAN JW. Classification and diagnosis of myelopro- liferative neoplasms:the 2008 World Health Organization criteria an point- of- care diagnostic algorithms[J]. Leukemia ,2008,22 : 14-22.
8CAROBBIO A,FINAZZI G,GUERINI V,et al. Leukocytosis is a risk factor for thrombosis in essential thrornboeythemia: interaction with treatment, standard risk factors, and JAK2 mutation status [J]. Blood, 2007,109 (6) :2310-2313.
9DE STEFANA V, ZA T, ROSSI E, et al. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the ho- mozygous JAK2V617F mutation [ J ]. Ann Hematol, 2010, 89 : 141- 146.
